Immunotoxin: A new tool for cancer therapy

Advances in Anticancer Immunotoxin Therapy

(2015) C. Alewine et al.   ONCOLOGIST

Immunotoxins for leukemia

(2014) A. S. Wayne et al.   BLOOD

GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells

(2013) Mrudula Mathew et al.   APOPTOSIS

Antitumor Activity of a Humanized, Bivalent Immunotoxin Targeting Fn14-Positive Solid Tumors

(2013) H. Zhou et al.   CANCER RESEARCH

The Insulin Receptor Negatively Regulates the Action of Pseudomonas Toxin-Based Immunotoxins and Native Pseudomonas Toxin

(2013) X. F. Liu et al.   CANCER RESEARCH

Abrin Immunotoxin: Targeted Cytotoxicity and Intracellular Trafficking Pathway

(2013) Sudarshan Gadadhar et al.   PLoS One

Immunotoxins: The Role of the Toxin

(2013) Antonella Antignani et al.   Toxins

Therapeutic targets and recent advances in protein immunotoxins

(2012) Madhumathi J et al.   CURRENT OPINION IN MICROBIOLOGY

Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines

(2012) Abid R. Mattoo et al.   INTERNATIONAL JOURNAL OF CANCER

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

(2012) W. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

(2012) H. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia

(2011) John Schindler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

(2011) D. J. FitzGerald et al.   CANCER RESEARCH

Therapeutic potential of anticancer immunotoxins

(2011) Swati Choudhary et al.   DRUG DISCOVERY TODAY

Design of Targeted B Cell Killing Agents

(2011) Alexey V. Stepanov et al.   PLoS One

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

(2011) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Research and development of next generation of antibody-based therapeutics

(2010) Jing Li et al.   ACTA PHARMACOLOGICA SINICA

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

(2010) B. Lowenberg et al.   BLOOD

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma

(2010) H. Miles Prince et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies

(2009) Robert J. Kreitman   BIODRUGS

Characterization of variant diphtheria toxin–interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials

(2009) Yunpeng Su et al.   BIOLOGICALS

Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy

(2009) Mrudula Mathew et al.   CANCER SCIENCE

A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia

(2009) Larry Herrera et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Whatever Happened to Immunotoxins? Research, and Hope, Are Still Alive

(2009) D. C. Holzman   JNCI-Journal of the National Cancer Institute

Cancer incidence and mortality in Iran

(2008) S. M. Mousavi et al.   ANNALS OF ONCOLOGY

Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity

(2008) X. Du et al.   CANCER RESEARCH

Monoclonal Antibodies as Innovative Therapeutics

(2008) Janice Reichert   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group

(2008) Richard Aplenc et al.   JOURNAL OF CLINICAL ONCOLOGY

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

(2008) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA